National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 3) (PB 34 of 2018) (Cth)

PB 34 of 2018

National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 3)

National Health Act 1953

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated      27 April 2018

LISA LA RANCE

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 3).

(2)   This Determination may also be cited as PB 34 of 2018.

1. Commencement

This Determination commences on 1 May 2018.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Adrenaline

Insert

Afatinib

[2]     Schedule 1, after item dealing with Ambrisentan

Insert

Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids

[3]     Schedule 1, after item dealing with Brexipiprazole

Insert

Brivaracetam

[4]     Schedule 2, after item dealing with Risedronic acid and Calcium

Omit

Risedronic acid and calcium with colecalciferol